# A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

> **NCT06775275** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Resectable Lung Non-Small Cell Carcinoma

## Interventions

- **DRUG:** Adebellizumab
- **DRUG:** Bevacizumab
- **DRUG:** Platinum-based chemotherapy

## Key facts

- **NCT ID:** NCT06775275
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-24
- **Primary completion:** 2025-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06775275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06775275, "A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06775275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*